Regeneron Pharmaceuticals REGN Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.97B-4.0% | $3.12B+25.5% | $2.51B+24.9% | $2.02B+4.5% | $3.09B+18.5% | ||
| $5.79B+10.1% | $5.49B-15.9% | $5.94B-23.7% | $5.47B-30.6% | $5.26B-33.6% | ||
| $5.73B+3.1% | $5.74B-7.6% | $5.69B-6.9% | $5.61B-1.9% | $5.56B+6.5% | ||
| $3.1B-2.8% | $3.2B+3.7% | $3.25B+7.8% | $3.21B+11.6% | $3.19B+17.6% | ||
| $18.21B+3.6% | $18.02B-3.4% | $17.98B-7.0% | $16.86B-11.6% | $17.57B-6.9% | ||
| $40.87B+8.9% | $40.56B+7.4% | $40.17B+7.3% | $38.22B+5.9% | $37.55B+9.2% | ||
| $1.03B+45.6% | $939M+18.9% | $903.8M+81.7% | $723.9M+28.9% | $705.5M+5.1% | ||
| $636.2M+2.7% | $553M-11.9% | $545.6M-13.0% | $481.9M-17.8% | $619.3M+19.9% | ||
| $5.11B+43.2% | $4.37B+10.8% | $4.43B+20.9% | $3.67B+4.5% | $3.57B-0.4% | ||
| $1.99B+0.1% | $1.99B+0.1% | $1.99B+0.1% | $1.99B+0.1% | $1.98B+0.1% | ||
| $9.45B+15.8% | $9.3B+10.7% | $9.21B+13.5% | $8.28B+5.1% | $8.16B+10.6% | ||
| $36.42B+12.5% | $35.8B+13.0% | $35.05B+14.0% | $33.68B+14.5% | $32.38B+15.7% | ||
| $31.42B+6.9% | $31.26B+6.5% | $30.96B+5.6% | $29.94B+6.1% | $29.39B+8.9% | ||
| $40.87B+8.9% | $40.56B+7.4% | $40.17B+7.3% | $38.22B+5.9% | $37.55B+9.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regeneron Pharmaceuticals's total assets?
- Regeneron Pharmaceuticals (REGN) holds $40.9B in total assets, up 8.8% year over year.
- How much debt does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals carries $2.7B in total debt against $31.4B of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Regeneron Pharmaceuticals have?
- Regeneron Pharmaceuticals holds $3.0B in cash and equivalents.
- Can Regeneron Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.56 — current assets exceed current liabilities.
- Where does Regeneron Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Regeneron Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
